Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent
Combination study to begin in 1st half 2023
SHANGHAI and SUZHOU, China, Nov. 27,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | China Health | Clinical Trials | Docetaxel | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Study | Taxotere